Search
Descriptor English: Cetuximab
Descriptor Spanish: Cetuximab
Descriptor cetuximab
Scope note: Un anticuerpo monoclonal quimérico que funciona como AGENTE ANTINEOPLÁSICO a través de su unión al RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDÉRMICO, donde se previene la acción de unión y de señalización del crecimiento celular y factores de supervivencia.
Descriptor Portuguese: Cetuximab
Descriptor French: Cétuximab
Entry term(s): C225
Erbitux
IMC C225
IMC-C225
MAb C225
Tree number(s): D12.776.124.486.485.114.224.060.750
D12.776.124.790.651.114.224.060.750
D12.776.377.715.548.114.224.200.750
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000068818
Scope note: A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Registry Number: PQX0D8J21J
Public MeSH Note: 2016; CETUXIMAB was indexed under ANTIBODIES, MONOCLONAL 2000-2013; and under ANTIBODIES, MONOCLONAL, HUMANIZED 2013-2015
History Note: 2016 (2000)
Related: ErbB Receptors MeSH
DeCS ID: 55975
Unique ID: D000068818
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2016/01/01
Date of Entry: 2015/07/01
Revision Date: 2018/07/02
Cetuximab - Preferred
Concept UI M0422675
Scope note A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
Preferred term Cetuximab
Erbitux - Narrower
Concept UI M0444717
Preferred term Erbitux
IMC C225 - Narrower
Concept UI M0366638
Preferred term IMC C225
Entry term(s) C225
IMC-C225
MAb C225



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey